ASCO 2024 Breast Cancer WC

CME

Conference to Clinic: Breast Cancer

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: July 02, 2024

Expiration: July 01, 2025

Kevin Kalinsky
Kevin Kalinsky, MD, MS

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following findings was reported from the DESTINY-Breast06 trial with trastuzumab deruxtecan vs physician’s choice of chemotherapy in patients with previously treated HR+/HER2-low or HER2-ultralow MBC who had not previously received chemotherapy for MBC?